{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T07:45:46Z","timestamp":1767858346810,"version":"3.49.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.ejpb.2014.05.008","type":"journal-article","created":{"date-parts":[[2014,5,22]],"date-time":"2014-05-22T03:46:25Z","timestamp":1400730385000},"page":"136-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Characterization and pharmacokinetic analysis of crystalline versus amorphous rapamycin dry powder via pulmonary administration in rats"],"prefix":"10.1016","volume":"88","author":[{"given":"Simone R.","family":"Carvalho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan B.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay I.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sha","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7570-6935","authenticated-orcid":false,"given":"Soraya","family":"Hengsawas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel S.","family":"Escotet-Espinoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert O.","family":"Williams III","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2014.05.008_b0005","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0041-1345(03)00211-2","article-title":"Sirolimus: its discovery, biological properties, and mechanism of action","volume":"35","author":"Sehgal","year":"2003","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.ejpb.2014.05.008_b0010","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1159\/000087945","article-title":"Patterns of pulmonary complications associated with sirolimus","volume":"73","author":"Chhajed","year":"2006","journal-title":"Respiration"},{"key":"10.1016\/j.ejpb.2014.05.008_b0015","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/j.healun.2013.01.990","article-title":"Use of sirolimus in lung transplantation: a single center experience","volume":"32","author":"Stuckey","year":"2013","journal-title":"J. Heart Lung Transplant."},{"key":"10.1016\/j.ejpb.2014.05.008_b0020","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and safety of sirolimus in lymphangioleiomyomatosis","volume":"364","author":"McCormack","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2014.05.008_b0025","doi-asserted-by":"crossref","first-page":"797","DOI":"10.7326\/0003-4819-154-12-201106210-00007","article-title":"Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus","volume":"154","author":"Taveira-DaSilva","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejpb.2014.05.008_b0030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0378-5173(00)00617-7","article-title":"Solubilization of rapamycin","volume":"213","author":"Simamora","year":"2001","journal-title":"Int. J. Pharm."},{"issue":"Suppl. 2","key":"10.1016\/j.ejpb.2014.05.008_b0035","doi-asserted-by":"crossref","first-page":"B101","DOI":"10.1016\/S0149-2918(00)89027-X","article-title":"Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus","volume":"22","author":"MacDonald","year":"2000","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejpb.2014.05.008_b0040","series-title":"Oral Lipid-Based Formulations: Enhancing the Bioavailability of Poorly Water-Soluble Drugs","author":"Hauss","year":"2007"},{"key":"10.1016\/j.ejpb.2014.05.008_b0045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/nano.2007.2.1.25","article-title":"Nanomedicines in renal transplant rejection \u2013 focus on sirolimus","volume":"2","author":"Shen","year":"2007","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2014.05.008_b0050","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2147\/IJN.S595","article-title":"Nanocrystal technology, drug delivery and clinical applications","author":"M\u00fcller","year":"2008","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2014.05.008_b0055","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00007890-199108000-00001","article-title":"Preclinical evaluation of a new potent immunosuppressive agent, rapamycin","volume":"52","author":"Kahan","year":"1991","journal-title":"Transplantation"},{"key":"10.1016\/j.ejpb.2014.05.008_b0060","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.2147\/IJN.S26546","article-title":"Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process","author":"Hwang","year":"2011","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2014.05.008_b0065","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3727\/000000004783983936","article-title":"Liposomal formulations of tacrolimus and rapamycin increase graft survival and fiber outgrowth of dopaminergic grafts","volume":"13","author":"Alemdar","year":"2004","journal-title":"Cell Transplant."},{"key":"10.1016\/j.ejpb.2014.05.008_b0070","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1080\/01932691.2010.488129","article-title":"Formulation of a poorly water-soluble drug sirolimus in solid dispersions to improve dissolution","volume":"32","author":"Preetham","year":"2011","journal-title":"J. Dispers. Sci. Technol."},{"key":"10.1016\/j.ejpb.2014.05.008_b0075","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrd2153","article-title":"Inhaling medicines: delivering drugs to the body through the lungs","volume":"6","author":"Patton","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejpb.2014.05.008_b0080","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejpb.2010.01.011","article-title":"Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats","volume":"75","author":"Yang","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2014.05.008_b0085","doi-asserted-by":"crossref","unstructured":"N.A. Beinborn, J. Du, N.P. Wiederhold, H.D.C. Smyth, R.O. Williams III, Dry powder insufflation of crystalline and amorphous voriconazole formulations produced by thin film freezing to mice, Eur. J. Pharm. Biopharm. (n.d.) 81 (2012) 600\u2013608.","DOI":"10.1016\/j.ejpb.2012.04.019"},{"key":"10.1016\/j.ejpb.2014.05.008_b0090","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejpb.2006.07.012","article-title":"Novel ultra-rapid freezing particle engineering process for enhancement of dissolution rates of poorly water-soluble drugs","volume":"65","author":"Overhoff","year":"2007","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2014.05.008_b0095","unstructured":"General Chapters <601> Aerosols, Nasal Sprays, Metered-dose Inhalers, and Dry Powder Inhaler, in: U.S. Pharmacop., 35th-NF ed., n.d."},{"key":"10.1016\/j.ejpb.2014.05.008_b0100","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1570-0232(02)00204-0","article-title":"Assessment of sirolimus concentrations in whole blood by high-performance liquid chromatography with ultraviolet detection","volume":"774","author":"Cattaneo","year":"2002","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.ejpb.2014.05.008_b0105","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jpba.2006.02.009","article-title":"Evaluation of rapamycin chemical stability in volatile-organic solvents by HPLC","volume":"41","author":"Ricciutelli","year":"2006","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejpb.2014.05.008_b0110","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3109\/08958378.2011.632787","article-title":"Regional particle size dependent deposition of inhaled aerosols in rats and mice","volume":"24","author":"Kuehl","year":"2012","journal-title":"Inhal. Toxicol."},{"key":"10.1016\/j.ejpb.2014.05.008_b0115","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nature08221","article-title":"Rapamycin fed late in life extends lifespan in genetically heterogeneous mice","volume":"460","author":"Harrison","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ejpb.2014.05.008_b0120","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/gerona\/glq178","article-title":"Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice","volume":"66A","author":"Miller","year":"2011","journal-title":"J. Gerontol. A: Biol. Sci. Med. Sci."},{"key":"10.1016\/j.ejpb.2014.05.008_b0125","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1474-9726.2011.00791.x","article-title":"Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1 ss and enhancing NMDA signaling","volume":"11","author":"Majumder","year":"2012","journal-title":"Aging Cell"},{"key":"10.1016\/j.ejpb.2014.05.008_b0130","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0939-6411(02)00063-2","article-title":"A novel particle engineering technology to enhance dissolution of poorly water soluble drugs: spray-freezing into liquid","volume":"54","author":"Rogers","year":"2002","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2014.05.008_b0135","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s11095-012-0922-2","article-title":"Respirable low-density microparticles formed in situ from aerosolized brittle matrices","volume":"30","author":"Watts","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2014.05.008_b0140","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1016\/j.carres.2006.04.040","article-title":"Glass transition and enthalpy relaxation of amorphous lactose glass","volume":"341","author":"Haque","year":"2006","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.ejpb.2014.05.008_b0145","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ijpharm.2003.10.039","article-title":"Alternative sugars as potential carriers for dry powder inhalations","volume":"270","author":"Steckel","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2014.05.008_b0150","first-page":"41","article-title":"Excipients used in lyophilization of small molecules","volume":"1","author":"Baheti","year":"2010","journal-title":"J. Excip. Food Chem."},{"key":"10.1016\/j.ejpb.2014.05.008_b0155","unstructured":"FisherScientific, Material Safety Data Sheet: Acetonitrile [HPLC], 2009."},{"key":"10.1016\/j.ejpb.2014.05.008_b0160","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1023\/A:1016087702409","article-title":"Dehydration mechanism and crystallisation behaviour of lactose","volume":"68","author":"Garnier","year":"2002","journal-title":"J. Therm. Anal. Calorim."},{"key":"10.1016\/j.ejpb.2014.05.008_b0165","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ejpb.2009.06.012","article-title":"Compatibility studies of acyclovir and lactose in physical mixtures and commercial tablets","volume":"73","author":"Monajjemzadeh","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2014.05.008_b0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1081\/PDT-120027417","article-title":"Micron-size drug particles: common and novel micronization techniques","volume":"9","author":"Rasenack","year":"2004","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejpb.2014.05.008_b0175","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0378-5173(94)90219-4","article-title":"Assessment of disorder in crystalline solids","volume":"101","author":"Saleki-Gerhardt","year":"1994","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2014.05.008_b0180","unstructured":"O. of the Commissioner, Inspection Guides \u2013 Lyophilization of Parenterals (7\/93) (n.d.)."},{"key":"10.1016\/j.ejpb.2014.05.008_b0185","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1208\/s12249-012-9797-0","article-title":"Effect of sampling volume on dry powder inhaler (DPI)-emitted aerosol aerodynamic particle size distributions (APSDs) measured by the next-generation pharmaceutical impactor (NGI) and the Andersen eight-stage cascade impactor (ACI)","volume":"13","author":"Mohammed","year":"2012","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2014.05.008_b0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2010.12.040","article-title":"Influence of particle size on regional lung deposition \u2013 what evidence is there?","volume":"406","author":"Carvalho","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2014.05.008_b0195","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00007890-199203000-00002","article-title":"The effect of rapamycin on kidney-function in the Sprague\u2013Dawley rat","volume":"53","author":"Dijoseph","year":"1992","journal-title":"Transplantation"},{"key":"10.1016\/j.ejpb.2014.05.008_b0200","series-title":"Prog. Immunol.","first-page":"1195","article-title":"Rapamycin: a new and highly active immunosuppressive macrolide with an efficacy superior to cyclosporine","author":"Meiser","year":"1989"},{"key":"10.1016\/j.ejpb.2014.05.008_b0205","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1053-2498(98)00020-5","article-title":"Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine","volume":"18","author":"Hausen","year":"1999","journal-title":"J. Heart Lung Transplant. Off. Publ. Int. Soc. Heart Transplant."},{"key":"10.1016\/j.ejpb.2014.05.008_b0210","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0009-9120(96)00157-9","article-title":"Distribution of sirolimus in rat tissue","volume":"30","author":"Napoli","year":"1997","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ejpb.2014.05.008_b0215","doi-asserted-by":"crossref","first-page":"S407","DOI":"10.1016\/0021-8502(90)90267-2","article-title":"Short-term and long-term clearance of particles from the upper human respiratory tract as function of particle size","volume":"21","author":"Stahlhofen","year":"1990","journal-title":"J. Aerosol Sci."},{"key":"10.1016\/j.ejpb.2014.05.008_b0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/03639040903092319","article-title":"Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilization on pharmacokinetic properties","volume":"36","author":"Tolman","year":"2010","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2014.05.008_b0225","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00280-007-0458-z","article-title":"Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(epsilon-caprolactone) micelles of rapamycin","volume":"61","author":"Yanez","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejpb.2014.05.008_b0230","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1513\/pats.200409-049TA","article-title":"The lungs as a portal of entry for systemic drug delivery (thoracic)","volume":"1","author":"Patton","year":"2004","journal-title":"Am. Thorac. Soc."},{"key":"10.1016\/j.ejpb.2014.05.008_b0235","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0378-4274(94)90018-3","article-title":"Pulmonary retention and clearance of particles","volume":"72","author":"Ferin","year":"1994","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.ejpb.2014.05.008_b0240","doi-asserted-by":"crossref","first-page":"L1002","DOI":"10.1152\/ajplung.00260.2003","article-title":"Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules","volume":"286","author":"Lombry","year":"2004","journal-title":"Am. J. Physiol.-Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.ejpb.2014.05.008_b0245","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1046\/j.1365-2125.2003.01892.x","article-title":"Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications","volume":"56","author":"Labiris","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2014.05.008_b0250","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s11095-009-0021-1","article-title":"Understanding the behavior of amorphous pharmaceutical systems during dissolution","volume":"27","author":"Alonzo","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2014.05.008_b0255","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/03639040500529176","article-title":"Supersaturation produces high bioavailability of amorphous danazol particles formed by evaporative precipitation into aqueous solution and spray freezing into liquid technologies","volume":"32","author":"Vaughn","year":"2006","journal-title":"Drug Dev. Ind. Pharm."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093964111400157X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093964111400157X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T14:47:25Z","timestamp":1565448445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S093964111400157X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S093964111400157X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2014.05.008","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization and pharmacokinetic analysis of crystalline versus amorphous rapamycin dry powder via pulmonary administration in rats","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2014.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}